Journal of Applied Biological Chemistry

  • Volume 66
  • /
  • Pages.138-143
  • /
  • 2023
  • /
  • 1976-0442(pISSN)
  • /
  • 2234-7941(eISSN)
The Korean Society for Applied Biological Chemistry (한국응용생명화학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of liver fibrosis by sensitization of human hepatic stellate cells by combined treatment with galtanin and TARIL

  • Dong-Oh Moon (Department of Biology Education, Daegu University)
  • Received : 2023.02.18
  • Accepted : 2023.03.29
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Liver fibrosis is caused by metabolic problems such as cholestasis, genetic problems, or viral infections. Inhibiting hepatic stellate cell (HSC) activation or inducing selective apoptosis of activated HSCs is used as a treatment strategy for liver fibrosis. It has been reported that when HSCs are activated, their apoptosis sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is enhanced because the expression of death receptor 5 is elevated. Finding a natural compound that can enhance the apoptotic effect of TRAIL on HSCs is a necessary strategy for liver fibrosis treatment. It was confirmed here that mangosteen-derived gartanin increased the effect of TRAIL-induced apoptosis by increasing the expression of DR5 in a p38-dependent manner in the hepatic stellate cell line LX-2. Combined treatment with gartanin and TRAIL accelerated DNA cleavage through caspase-3 activation and enhanced antifibrotic effects in LX-2 cells.

Keywords

Acknowledgement

The present study was partly supported by a Daegu University Research Grant (Gyeongsan, Korea) awarded in 2018 (No. 2018-0398).

References

  1. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332: 1519-1523. doi: 10.1126/science.120426
  2. Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol Mech Dis 6: 425-456. doi: 10.1146/annurev-pathol011110-130246
  3. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14: 181-194. doi: 10.1038/nri3623
  4. Bataller R, Brenner DA (2001) Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 21: 437-452. doi: 10.1055/s-2001-17558
  5. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, Serriere-Lanneau V, Ledent C, Mallat A, Lotersztajn S (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676. doi: 10.1038/nm1421
  6. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA (2005) Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128: 108-120. doi: 10.1053/j.gastro.2004.10.003
  7. Kim KM, Yoon JH, Gwak GY, Kim W, Lee SH, Jang JJ, Lee HS (2006) Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells. Biochem Biophys Res Commun 342: 1108-1113. doi: 10.1016/j.bbrc.2006.02.072
  8. Pinzani M, Rombouts K, Colagrande S (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 Supp(l): S22-36. doi: 10.1016/j.jhep.2004.12.008
  9. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163. doi: 10.1038/5517
  10. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960. doi: 10.1038/91000
  11. Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T (2009) TRAIL-induced apoptosis: between tumor therapy and immunopathology. Ann N Y Acad Sci 1171: 50-58. doi: 10.1111/j.1749-6632.2009.04905.x
  12. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482: 193-199. doi: 10.1016/s0014-5793(00)02042-1
  13. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ (2003) Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37: 87-95. doi: 10.1053/jhep.2003.50002
  14. Arabpour M, Cool RH, Faber KN, Quax WJ, Haisma HJ (2017) Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells. J Drug Target 25(4): 360-369. doi: 10.1080/1061186X.2016.1262867
  15. Xu F, Zhou D, Meng X, Wang X, Liu C, Huang C, Li J, Zhang L (2016) Smad2 increases the apoptosis of activated human hepatic stellate cells induced by TRAIL. Int. Immunopharmacol 32: 76-86. doi: 10.1016/j.intimp.2016.01.013
  16. Pedraza-Chaverri J, Cardenas-Rodriguez N, Orozco-Ibarra M, Perez-Rojas JM (2008) Medicinal properties of mangosteen (Garcinia mangostana). Food Chem Toxicol 46: 3227-3239. doi: 10.1016/j.fct.2008.07.024
  17. Han AR, Kim JA, Lantvit DD, Kardono LB, Riswan S, Chai H, Carcache de Blanco EJ, Farnsworth NR, Swanson SM, Kinghorn AD (2009) Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen). J Nat Prod 72: 2028-2031. doi: 10.1021/np900517h
  18. Kim MO, Lee HS, Chin YW, Moon DO, Ahn JS (2015) Gartanin induces autophagy through JNK activation which extenuates caspase-dependent apoptosis. Oncol Rep 34:139-146. doi: 10.3892/or.2015.3948
  19. Luo M, Liu Q, He M, Yu Z, Pi R, Li M, Yang X, Wang S, Liu A (2017) Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells. J Cell Mol Med 21: 46-57. doi: 10.1111/jcmm.12937
  20. Moon DO (2023) Gartanin enhances TRAIL-mediated liver cancer cell death through DR5 upregulation and autophagy activation. J Appl Biol Chem 66: 53-59. doi: 10.3839/jabc.2023.008
  21. Han KH, Yoon KT (2008) New diagnostic methods for liver fibrosis and cirrhosis. Intervirology. 51: 11-16. doi: 10.1159/000122594
  22. Ren LL, Li XJ, Duan TT, Li ZH, Yang JZ, Zhang YM, Zou L, Miao H, Zhao YY (2023) Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities. Chem Biol Interact 5; 369: 110289. doi: 10.1016/j.cbi.2022.110289
  23. Tang X, Yang J, Li J (2009) Accelerative effect of leflunomide on recovery from hepatic fibrosis involves TRAIL-mediated hepatic stellate cell apoptosis. Life Sci 84(15-16): 552-557. doi: 10.1016/j.lfs.2009.01.017
  24. Oh Y, Park O, Swierczewska M, Hamilton JP, Park JS, Kim TH, Lim SM, Eom H, Jo DG, Lee CE, Kechrid R, Mastorakos P, Zhang C, Hahn SK, Jeon OC, Byun Y, Kim K, Hanes J, Lee KC, Pomper MG, Gao B, Lee S (2016) Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Hepatology 64 (1): 209-223. doi: 10.1002/hep.28432